Intervention

Exemestane 25 MG

ClinicalTrials.gov intervention label

Clinical trials5

Recruiting3

Common conditions12

Lead sponsors shown5

Clinical trials

5 shown

Sapu003 in Advanced mTOR-sensitive Solid TumorsNCT07369505 · 2025-12-15

Low Dose Exemestane vs Low Dose Tamoxifen in Post-menopausal Women at High Risk for Breast Cancer.NCT06364267 · 2025-10-01

Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)NCT05512364 · 2023-12-15

Aromatase Inhibitor and Durvalumab in Postmenopausal Breast CancerNCT03874325 · 2019-04-26

A Study Evaluating Megestrol Acetate Modulation in Hormone Receptor Positive Advanced Breast CancerNCT03024580 · 2017-03-06

Common conditions

Breast Cancer2 Breast Cancer Metastatic1 Breast Neoplasm1 ER-positive Breast Cancer1 Hepatocellular Carcinoma (HCC)1 HER2-negative Breast Cancer1 Hormone Receptor Positive Tumor1 Neuroendocrine Tumors1 Renal Cell Carcinoma (RCC)1 Stage IIB Breast Cancer1 Stage III Breast Cancer1 Tuberous Sclerosis Complex (TSC)1

Leading sponsors

Andrea DeCensi1 European Organisation for Research and Treatment of Cancer - EORTC1 H. Lee Moffitt Cancer Center and Research Institute1 Instituto Nacional de Cancer, Brazil1 SAPU NANO (US) LLC1

Trial status mix

RECRUITING3

TERMINATED1

UNKNOWN1

Phase mix

PHASE23

PHASE11

PHASE31

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.